Open insulin, 'DIY bio' and the future of pharma

September 13, 2018, Colorado State University

The development, manufacture and sale of pharmaceutical drugs in the United States is a complex landscape involving intellectual property and strict federal regulations.

But according to Colorado State University scientists, the status quo of the U.S. pharmaceutical market may soon be turned on its head. That's due in part to a growing community of do-it-yourself "biohackers" who are disrupting business-as-usual for pharmaceutical discovery, development and distribution.

A Sept. 13 perspective piece in Trends in Biotechnology frames these emerging issues, and predicts how the pharmaceutical industry, and the U.S. regulatory environment, will need to change in response. The paper's authors are Jean Peccoud, the Abell Chair in Synthetic Biology in the Department of Chemical and Biological Engineering; Jenna Gallegos, a postdoctoral researcher in the Department of Chemical and Biological Engineering; and collaborators from Bio-Link Australia, Woodrow Wilson International Center for Scholars and Boston University School of Public Health. Peccoud is also a faculty member in the School of Biomedical Engineering at CSU.

As the prices of many medicines continue to rise, new models of funding, research and development have emerged as part of what the authors call a "novel innovation ecosystem." Most notably, this ecosystem involves drug manufacturing at smaller, more personalized scales.

"Key drugs are still too expensive," Peccoud said. "People don't have access to them, so what if they can make it themselves? What do we do about that?"

The authors use the California-based Open Insulin Project as a case study of how the DIY bio movement might shape the future of medicine. Founded in 2015, the project's creators are trying to increase competition in the insulin market by developing and releasing an open-source protocol for manufacturing off-patent insulin.

Why does the Open Insulin Project exist in the first place? Insulin is 100 years old, but it remains prohibitively expensive for many patients, with some uninsured patients paying up to $400 a month for this life-saving medicine. People are angry, and in some cases, people are dying, from lack of access to affordable insulin.

The U.S. regulatory system today favors existing manufacturers of biologic drugs like insulin. Biologics are drugs made from a living organism, as opposed to small-molecule drugs, such as aspirin, which are synthesized chemically. When making off-patent small-molecule drugs, a competing company need only demonstrate that they've made pure aspirin. But biologic drugs are more difficult to control for quality; thus competing companies have to do expensive human clinical trials—not worth the $250 million price tag, if they can't even file for a patent to recoup their investments.

While the structure of human insulin is no longer patent protected, the handful of large companies that produce insulin continue to market "" that are supposedly improved varieties of plain insulin. The authors note that the medical benefits of these new versions of insulin are debatable.

That's where the biohackers come in. If the Open Insulin Project succeeds in developing a protocol for "home-brewed" insulin, they'll need to avoid violating patent-protected methods of manufacturing insulin. But biohackers making insulin for their own, personal use wouldn't need to worry about patent infringement—although safety considerations are certainly at play.

"It would be prudent for regulators to engage patients and innovators in community bio-labs to design adaptive oversight that fosters an ethos of responsibility," the authors say.

The real challenge for Open Insulin Project biohackers, should they want to enable competing pharmaceutical companies to sell off-patent insulin, will be regulation, the authors say. The success of the project will be severely limited by the cost of regulatory approvals, which include proving biological consistency, safety and possibly efficacy.

If such new models of are to succeed, they will depend on alternative approval processes, the authors say. If biosimilarity of biohacked could be confirmed without clinical trials, the cost of development would dramatically decrease. This could be achieved through smaller-scale, decentralized manufacturing. And the technology already exists; microbioreactors that are capable of producing smaller doses of biologics have been developed in university labs.

"In short, the status quo has got to change," Gallegos said. "We can't address the issues if we don't acknowledge them."

Explore further: Increasing cost of insulin has serious health consequences

Related Stories

Increasing cost of insulin has serious health consequences

August 4, 2018

(HealthDay)—The increasing cost of insulin is potentially exposing those with diabetes to serious health consequences, according to an American Diabetes Association statement published in the June issue of Diabetes Care.

WHO issues recommendations for Tx intensification in T2DM

September 5, 2018

(HealthDay)—Recommendations have been developed by the World Health Organization for treatment intensification in type 2 diabetes. The recommendations were published online Sept. 4 in the Annals of Internal Medicine.

Recommended for you

Meteorite source in asteroid belt not a single debris field

February 17, 2019

A new study published online in Meteoritics and Planetary Science finds that our most common meteorites, those known as L chondrites, come from at least two different debris fields in the asteroid belt. The belt contains ...

Diagnosing 'art acne' in Georgia O'Keeffe's paintings

February 17, 2019

Even Georgia O'Keeffe noticed the pin-sized blisters bubbling on the surface of her paintings. For decades, conservationists and scholars assumed these tiny protrusions were grains of sand, kicked up from the New Mexico desert ...

Archaeologists discover Incan tomb in Peru

February 16, 2019

Peruvian archaeologists discovered an Incan tomb in the north of the country where an elite member of the pre-Columbian empire was buried, one of the investigators announced Friday.

Where is the universe hiding its missing mass?

February 15, 2019

Astronomers have spent decades looking for something that sounds like it would be hard to miss: about a third of the "normal" matter in the Universe. New results from NASA's Chandra X-ray Observatory may have helped them ...

What rising seas mean for local economies

February 15, 2019

Impacts from climate change are not always easy to see. But for many local businesses in coastal communities across the United States, the evidence is right outside their doors—or in their parking lots.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (1) Sep 13, 2018
Drug companies have increased the price they charge for insulin by 400 to 600 percent over the last decade or so.

There is no justification, and the only explanation is pure greed.

The patent for Insulin was sold by it's Canadian discoverers for $1,.00.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.